Photodynamic therapy (PDT), which uses a light-sensitive chemical known as a photosensitizer to produce cell-killing “reactive oxygen,” has become an important option for the treatment of esophageal cancer and non-small cell lung cancer. Current photosensitizers, however, produce significant side effects, including sensitivity to the sun, that limits their wider use in treating cancer.
In an attempt to both eliminate those side effects and increase the anticancer activity of photosensitizers, a multi-institutional research team led by Ralph Weissleder, M.D., co-director of the MIT-Harvard Center of Cancer Nanotechnology Excellence, has developed a polymer nanoparticle to ferry photosensitizers into cancer cells, where they can then unleash their potent cell-killing effects. The investigators report their work in the journal Nano Letters.
Dr. Weissleder and his colleagues created nanoparticles from a biodegradable polymer known as poly(lactic-co-glycolic acid), and used these nanoparticles to encapsulate a photosensitizer designed to aggregate, or clump together, within the nanoparticle. Such aggregation prevents the photosensitizer molecules from being activated by light, rendering them non-toxic while circulating in the bloodstream. But once the nanoparticles are taken up by cancer cells, they fall apart and release the photosensitizer molecules, which then disaggregate. As a result, the photosensitizers become active once more and can kill cancer cells when irradiated with light. When stored in the dark at room temperature, the nanoparticle-photosensitizer formulation is stable for 6 to 12 months.
Experiments using cancer cells grown in culture dishes showed conclusively that the nanoparticle-photosensitizer formulation had little toxicity to cells unless taken up within the cells. The investigators also conducted tests in which they injected this formulation into tumor-bearing mice and then administered light therapy 24 hours later. This experiment confirmed that the nanoparticle-borne photosensitizer accumulated in tumor cells and was capable of killing those cells when exposed to light.
This work, funded in part by the National Cancer Institute, is detailed in a paper titled, “Polymeric nanoparticle preparation that eradicates tumors.” Investigators from the University of Connecticut and the University of Central Florida also participated in this study. An abstract is available through
PubMed.
Source: National Cancer Institute
Related stories:
Nanoparticles + light = dead tumor cells
Medical physicists at the University of Virginia have created a novel way to kill tumor cells using nanoparticles and light. The technique, devised by Wensha Yang, an instructor in radiation oncology at the University of Virginia, and colleagues Ke Sheng, Paul W. Read, James M. Larner, and Brian P. Helmke, employs quantum dots. Quantum dots are semiconductor nanostructures, 25 billionths of a meter in diameter, which can confine electrons in three dimensions and emit light when exposed to ultraviolet radiation.
Nanoparticles Yield Safer Light-Activated Cancer Therapy
Photodynamic therapy, in which light activates a chemical known as a photosensitizer, triggering the production of cell-killing reactive oxygen, has proven itself as an effective therapy for a limited number of cancers.
Watery Nanoparticles Deliver Anticancer Therapy
Ultrafine nanoparticles made of a lacy web of polymer and tiny pockets of water may prove to be an ideal vehicle for delivering light-activated drugs to tumors. Preliminary experiments, published in the journal
Angewandte Chemie International Edition, show that cancer cells die quickly when treated with these nanoparticles and exposed to light.
Nanoparticle Enables Light-Activated Ovarian Cancer Detection and Therapy
By combining a compound produced by the plant St. John’s wort with polymeric nanoparticles, researchers at the University of Geneva in Switzerland have developed a promising method for treating ovarian tumors using light. Perhaps more importantly, this nanoscale construct may also enable surgeons to detect the microscopic metastatic tumors that often remain after surgery but lead to cancer recurring years after initial therapy.
Studies spot numerous undiscovered gene alterations in pancreatic and brain cancers
HHMI investigators have detected a multitude of broken, missing, and overactive genes in pancreatic and brain tumors, in the most detailed genetic survey yet of any human tumor. Some of these genetic changes were previously unknown and could provide new leads for improved diagnosis and therapy for these devastating cancers.
You can be replaced: Immune cells compensate for defective DNA repair factor
A new mouse model has provided some surprising insight into XLF, a molecule that helps to repair lethal DNA damage. The research, published by Cell Press in the September 5th issue of the journal
Molecular Cell, suggests that although XLF shares many properties with well known DNA repair factors, certain cells of the immune system possess an unexpected compensatory mechanism that that can take over for nonfunctional XLF.
Unsuccessful drug against anxiety opens a novel gateway for the treatment of cancer
Unsatisfying drug for anxiety reveals scientists a promising novel anti-cancer drug target. Cancer cells have multiple ways to avoid apoptosis, programmed cell death the means by which organisms deal with defective cells. One defense is to produce quantities of phosphatic acid, a phospholipid constituent of cellular membranes.
Stem cell research puts interstate rivalry on hold
Victoria and New South Wales have put aside their competitive interstate rivalry to collaborate on a stem cell research project, as announced by Innovation Minister Gavin Jennings and NSW Minister for Science and Medical Research, Verity Firth, today.